Rhumbline Advisers Kezar Life Sciences, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.6 - $0.92 $49,130 - $75,333	-81,884 Reduced 74.82%	27,551 $16,000
Q1 2024 May 09, 2024	BUY	$0.8 - $1.05 $2,064 - $2,709	2,580 Added 2.41%	109,435 $98,000
Q3 2023 Nov 09, 2023	SELL	$1.08 - $2.54 $7,234 - $17,015	-6,699 Reduced 5.9%	106,855 $127,000
Q2 2023 Aug 08, 2023	BUY	$2.31 - $3.06 $72,859 - $96,515	31,541 Added 38.46%	113,554 $278,000
Q1 2023 May 11, 2023	BUY	$3.13 - $7.31 $7,142 - $16,681	2,282 Added 2.86%	82,013 $257,000
Q4 2022 Feb 14, 2023	BUY	$6.39 - $8.8 $5,591 - $7,700	875 Added 1.11%	79,731 $561,000
Q3 2022 Nov 10, 2022	BUY	$7.99 - $10.75 $99,795 - $134,267	12,490 Added 18.82%	78,856 $679,000
Q2 2022 Aug 11, 2022	BUY	$4.58 - $17.13 $90,908 - $340,013	19,849 Added 42.67%	66,366 $549,000
Q1 2022 May 12, 2022	BUY	$12.3 - $18.33 $74,427 - $110,914	6,051 Added 14.95%	46,517 $773,000
Q4 2021 Feb 10, 2022	BUY	$7.44 - $16.72 $4,010 - $9,012	539 Added 1.35%	40,466 $677,000
Q3 2021 Nov 12, 2021	BUY	$4.85 - $9.73 $5,228 - $10,488	1,078 Added 2.77%	39,927 $345,000
Q2 2021 Aug 05, 2021	SELL	$4.93 - $6.46 $10,555 - $13,830	-2,141 Reduced 5.22%	38,849 $211,000
Q1 2021 May 06, 2021	SELL	$5.24 - $6.99 $10,427 - $13,910	-1,990 Reduced 4.63%	40,990 $244,000
Q4 2020 Feb 10, 2021	BUY	$4.77 - $6.58 $34,510 - $47,606	7,235 Added 20.24%	42,980 $224,000
Q3 2020 Nov 12, 2020	SELL	$4.36 - $5.5 $19,179 - $24,194	-4,399 Reduced 10.96%	35,745 $173,000
Q2 2020 Aug 13, 2020	BUY	$3.6 - $7.75 $30,956 - $66,642	8,599 Added 27.26%	40,144 $208,000
Q1 2020 May 06, 2020	BUY	$2.77 - $5.75 $27,132 - $56,321	9,795 Added 45.03%	31,545 $138,000
Q4 2019 Feb 05, 2020	SELL	$2.5 - $4.26 $440 - $749	-176 Reduced 0.8%	21,750 $87,000
Q3 2019 Oct 23, 2019	BUY	$3.0 - $7.58 $5,574 - $14,083	1,858 Added 9.26%	21,926 $72,000
Q2 2019 Aug 14, 2019	BUY	$7.09 - $21.9 $44,404 - $137,159	6,263 Added 45.37%	20,068 $155,000
Q1 2019 May 01, 2019	BUY	$16.83 - $23.75 $232,338 - $327,868	13,805 New	13,805 $245,000

Others Institutions Holding KZR

# of Institutions

Shares Held

38.4M

Call Options Held

13.8K

Put Options Held

600

Suvretta Capital Management, LLC New York, NY

7.17M
Shares

$46.7 Million
0.22% of portfolio
Avidity Partners Management LP Dallas, TX

5.03M
Shares

$32.8 Million
0.24% of portfolio
Tang Capital Management LLC San Diego, CA

3.64M
Shares

$23.7 Million
0.24% of portfolio
Vanguard Group Inc Valley Forge, PA

2.74M
Shares

$17.9 Million
0.0% of portfolio
Affinity Asset Advisors, LLC New York, NY

2.51M
Shares

$16.4 Million
0.33% of portfolio

View Full List

About Kezar Life Sciences, Inc.

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

More about KZR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account